Search QAs

Which intra-group transaction ID should be reported in case the transaction is part of a single economic transaction?

Shall exposures with the same external counterparty that are labelled in different currencies should be reported in separate lines?

In FC.01 should we report equity securities at consolidated value or social value?

In which category must be reported investments in funds (FC01/FC0120/Instrument)?

What is the intended difference in information and insight for Direct Business for QRT S.04.04 vs S.04.05?

In relation to columns C0110 and C0120, you refer to claims that "have been settled with payment during the reporting year". Should the claims, on which the payment occured during the year, but they are for some reason still OPEN at the year-end (thus they are not fully settled) be also included or not?

Question 2433 clarifies that the non-life lapse risk shall be based on "policies for which discontinuance would result in an increase of technical provisions" (directive text) "before the payments caused by the discontinuance are made" (Q&A clarification). With this clarification, discontinuance of any profitable contract will result in a (short term) increase in the provisions and are thus within scope of the Lapse risk calculation.

We have a question regarding S.37.01 Cell C0320 – Exemptions (included in the Implementing Regulation 2023/894), where we seek clarification of what information is asked for specifically. The cell C0320 makes reference to Article 187 in the delegated regulation, and in its reporting events, EIOPA has also referred to the banking regulation (Article 400 in the Regulation (EU) No 575/2013); We understand this is because both articles/legislations are referred to in the FICOD reporting requirements (Implementing Regulation 2022/2454, template FC.06, cell FC0270).

Is the column "Maximum cover by transaction" (C0150) meant to include only internal reinsurance?